Literature DB >> 21525224

Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus.

Yukiko Watanabe1, Longzhu Cui, Yuki Katayama, Kishii Kozue, Keiichi Hiramatsu.   

Abstract

Of 38 vancomycin-intermediate Staphylococcus aureus (VISA) clinical strains, 27 (71%) possessed a mutation(s) in rpoB encoding the β-subunit of RNA polymerase. Furthermore, 95.6% of the rifampin-resistant mutants obtained from 9 methicillin-resistant S. aureus (MRSA) clinical isolates showed decreased vancomycin susceptibilities. These data indicate the involvement of an rpoB mutation in VISA phenotype expression.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21525224      PMCID： PMC3147882          DOI： 10.1128/JCM.02144-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  21 in total

1.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.

Authors:  Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

2.  Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.

Authors:  A J O'Neill; T Huovinen; C W G Fishwick; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Staphylococcus aureus infections.

Authors:  F D Lowy
Journal:  N Engl J Med       Date:  1998-08-20       Impact factor: 91.245

4.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

5.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

6.  Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community.

Authors:  Keiko Okuma; Kozue Iwakawa; John D Turnidge; Warren B Grubb; Jan M Bell; Frances G O'Brien; Geoffrey W Coombs; John W Pearman; Fred C Tenover; Maria Kapi; Chuntima Tiensasitorn; Teruyo Ito; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

7.  DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Jian-Qi Lian; Hui-Min Neoh; Ethel Reyes; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.

Authors:  Longzhu Cui; Taisuke Isii; Minoru Fukuda; Tomonori Ochiai; Hui-Min Neoh; Ilana Lopes Baratella da Cunha Camargo; Yukiko Watanabe; Mitsutaka Shoji; Tomomi Hishinuma; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

9.  Antimicrobial therapy for methicillin-resistant Staphylococcus aureus colonization in residents and staff of a Veterans Affairs nursing home care unit.

Authors:  L J Strausbaugh; C Jacobson; D L Sewell; S Potter; T T Ward
Journal:  Infect Control Hosp Epidemiol       Date:  1992-03       Impact factor: 3.254

10.  In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey.

Authors:  Hong Bin Kim; Hee-Chang Jang; Hee Jung Nam; Yeong Seon Lee; Bong Su Kim; Wan Beom Park; Ki Deok Lee; Young Joo Choi; Sang Won Park; Myoung-Don Oh; Eui-Chong Kim; Kang Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  49 in total

1.  Rifampin Resistance rpoB Alleles or Multicopy Thioredoxin/Thioredoxin Reductase Suppresses the Lethality of Disruption of the Global Stress Regulator spx in Staphylococcus aureus.

Authors:  Maite Villanueva; Ambre Jousselin; Kristoffer T Baek; Julien Prados; Diego O Andrey; Adriana Renzoni; Hanne Ingmer; Dorte Frees; William L Kelley
Journal:  J Bacteriol       Date:  2016-09-09       Impact factor: 3.490

2.  The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus.

Authors:  Wei Gao; David R Cameron; John K Davies; Xenia Kostoulias; Justin Stepnell; Kellie L Tuck; Michael R Yeaman; Anton Y Peleg; Timothy P Stinear; Benjamin P Howden
Journal:  J Infect Dis       Date:  2012-12-18       Impact factor: 5.226

3.  Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.

Authors:  Miki Matsuo; Longzhu Cui; Jeeyoung Kim; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

Review 4.  Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.

Authors:  Daina Zeng; Dmitri Debabov; Theresa L Hartsell; Raul J Cano; Stacy Adams; Jessica A Schuyler; Ronald McMillan; John L Pace
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

5.  Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.

Authors:  Miki Matsuo; Tomomi Hishinuma; Yuki Katayama; Longzhu Cui; Maria Kapi; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

6.  A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".

Authors:  Miki Matsuo; Tomomi Hishinuma; Yuki Katayama; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

7.  Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.

Authors:  Celine Vidaillac; Susana Gardete; Ryan Tewhey; George Sakoulas; Glenn W Kaatz; Warren E Rose; Alexander Tomasz; Michael J Rybak
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

8.  A mutation of the RNA polymerase β' subunit (rpoC) confers cephalosporin resistance in Bacillus subtilis.

Authors:  Yong Heon Lee; Ki Hyun Nam; John D Helmann
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

9.  Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene.

Authors:  Kristoffer T Bæk; Louise Thøgersen; René G Mogenssen; Maiken Mellergaard; Line E Thomsen; Andreas Petersen; Søren Skov; David R Cameron; Anton Y Peleg; Dorte Frees
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

10.  Mutation of RNA polymerase β-subunit gene promotes heterogeneous-to-homogeneous conversion of β-lactam resistance in methicillin-resistant Staphylococcus aureus.

Authors:  Yoshifumi Aiba; Yuki Katayama; Tomomi Hishinuma; Hiroko Murakami-Kuroda; Longzhu Cui; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.